Kimberly E Vanover Selected Research

Investigational Drugs

2/2016	Discovery of Potent and Selective Inhibitors of Phosphodiesterase 1 for the Treatment of Cognitive Impairment Associated with Neurodegenerative and Neuropsychiatric Diseases.
1/2016	ITI-007 for the Treatment of Schizophrenia: A 4-Week Randomized, Double-Blind, Controlled Trial.
8/2015	ITI-007 demonstrates brain occupancy at serotonin 5-HT₂A and dopamine D₂ receptors and serotonin transporters using positron emission tomography in healthy volunteers.
3/2014	Discovery of a tetracyclic quinoxaline derivative as a potent and orally active multifunctional drug candidate for the treatment of neuropsychiatric and neurological disorders.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kimberly E Vanover Research Topics

Disease

11	Schizophrenia (Dementia Praecox) 01/2021 - 01/2014
3	Sleepiness 12/2021 - 01/2021
3	Hallucinations (Hallucination) 01/2017 - 01/2014
2	Movement Disorders (Movement Disorder) 01/2019 - 02/2016
2	Parkinson Disease (Parkinson's Disease) 10/2008 - 07/2003
2	Catalepsy 06/2008 - 08/2007
2	Psychotic Disorders (Schizoaffective Disorder) 09/2004 - 07/2003
1	Nausea 12/2021
1	Headache (Headaches) 01/2021
1	Weight Gain 01/2021
1	Body Weight (Weight, Body) 01/2021
1	Hyperprolactinemia 01/2019
1	Psychomotor Agitation (Akathisia) 01/2019
1	Mental Disorders (Mental Disorder) 01/2017
1	Neurobehavioral Manifestations 01/2017
1	Alzheimer Disease (Alzheimer's Disease) 02/2016
1	Cognitive Dysfunction 02/2016
1	Mood Disorders (Mood Disorder) 08/2015
1	Nervous System Diseases (Neurological Disorders) 03/2014
1	Sleep Initiation and Maintenance Disorders (Insomnia) 01/2010
1	Tremor (Tremors) 10/2008
1	Dyskinesias (Dyskinesia) 10/2008

Drug/Important Bio-Agent (IBA)

9	lumateperoneIBA 12/2021 - 01/2014
9	Antipsychotic Agents (Antipsychotics)IBA 01/2021 - 07/2003
6	Dopamine (Intropin)FDA LinkGeneric 01/2021 - 01/2014
4	Serotonin (5 Hydroxytryptamine)IBA 01/2021 - 10/2008
4	Glutamic Acid (Glutamate)FDA Link 01/2021 - 01/2017
4	Investigational DrugsIBA 02/2016 - 03/2014
3	5-HT2A Serotonin Receptor (5 HT2A Receptor)IBA 01/2010 - 07/2003
2	Neurotransmitter Agents (Neurotransmitter)IBA 01/2021 - 01/2016
2	Risperidone (Risperdal Consta)FDA LinkGeneric 01/2021 - 08/2007
2	Pharmaceutical PreparationsIBA 01/2021 - 03/2014
2	Dopamine D2 Receptors (Dopamine D2 Receptor)IBA 01/2019 - 01/2017
2	Cyclic NucleotidesIBA 01/2017 - 01/2014
2	Cell Surface ReceptorsIBA 01/2017 - 01/2014
2	Phosphoric Diester Hydrolases (Phosphodiesterases)IBA 02/2016 - 01/2014
2	pimavanserinIBA 10/2008 - 08/2007
2	Haloperidol (Haldol)FDA LinkGeneric 06/2008 - 08/2007
1	ProlactinIBA 01/2021
1	Biological ProductsIBA 01/2021
1	LDL CholesterolIBA 01/2021
1	CholesterolIBA 01/2021
1	N-Methylaspartate (NMDA)IBA 01/2017
1	EnzymesIBA 01/2017
1	diethylstilbestrol monophosphate (PDES)IBA 01/2017
1	Dopamine Receptors (Dopamine Receptor)IBA 01/2016
1	QuinoxalinesIBA 03/2014
1	Dopamine D2 Receptor AntagonistsIBA 01/2014
1	Levodopa (L Dopa)FDA LinkGeneric 10/2008
1	PyrrolidinesIBA 10/2008
1	1- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)IBA 10/2008
1	Tacrine (Cognex)FDA Link 10/2008
1	SaltsIBA 10/2008
1	Urea (Carbamide)FDA LinkGeneric 10/2008
1	4- (3- (4- butylpiperidin- 1- yl)propyl)- 7- fluoro- 4H- benzo(1,4)oxazin- 3- oneIBA 06/2008
1	Apomorphine FDA Link 06/2008
1	Amphetamine (Amfetamine)FDA LinkGeneric 06/2008
1	2- (4- methoxyphenyl)- N- (4- methylbenzyl)- N- (1- methylpiperidin- 4- yl)acetamideIBA 09/2004

Therapy/Procedure

2	Therapeutics 01/2017 - 07/2003
1	Drug Therapy (Chemotherapy) 01/2021